Halberd News

Press releases and updates on our medical breakthroughs.

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By |2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Read More
Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By |2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine ...

Read More
Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By |2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Read More
Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By |2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Read More
Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Read More
Oct 25 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

By |2021-10-24T19:32:33-04:00October 25th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity.  Removal of these obesity-related target elements would reduce or eliminate ...

Read More
Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By |2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Read More
Oct 19 2021

Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

By |2021-10-19T20:51:31-04:00October 19th, 2021|Press Releases|Comments Off on Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and ...

Read More
Oct 19 2021

Insulin Resistance Associated To Obesity: The Link TNF-Alpha

By |2021-10-19T20:43:06-04:00October 19th, 2021|Press Releases|Comments Off on Insulin Resistance Associated To Obesity: The Link TNF-Alpha

Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, and obese mice ...

Read More
Oct 19 2021

Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

By |2021-10-19T20:34:25-04:00October 19th, 2021|Press Releases|Comments Off on Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

SOURCE: https://news.mit.edu/2016/fat-fighting-nanoparticles-obesity-0502   "Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects. The drugs work by transforming white adipose tissue, which is ...

Read More
INVESTOR/MEDIA INQUIRIES

MEDICAL METAVERSE

As part of our efforts to remain at the forefront of breakthrough technologies in the medical and scientific fields, Halberd Corporation is engaged in scientific study and research in the fields of medicine, the prevention, treatment and management of illness and infections and rapid tests to identify infection, and other medical maladies.

To learn more about how we can further your efforts, or to partner with Halberd on specific healthcare solutions, please email: info@halberdcorporation.com

Go to Top